466 related articles for article (PubMed ID: 33133102)
1. Plasma C4d Correlates With C4d Deposition in Kidneys and With Treatment Response in Lupus Nephritis Patients.
Martin M; Trattner R; Nilsson SC; Björk A; Zickert A; Blom AM; Gunnarsson I
Front Immunol; 2020; 11():582737. PubMed ID: 33133102
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis and significance of glomerular C4d deposition in lupus nephritis: activation of classical and lectin pathways.
Kim MK; Maeng YI; Lee SJ; Lee IH; Bae J; Kang YN; Park BT; Park KK
Int J Clin Exp Pathol; 2013; 6(10):2157-67. PubMed ID: 24133594
[TBL] [Abstract][Full Text] [Related]
3. Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study.
Batal I; Liang K; Bastacky S; Kiss LP; McHale T; Wilson NL; Paul B; Lertratanakul A; Ahearn JM; Manzi SM; Kao AH
Lupus; 2012 Jan; 21(1):13-26. PubMed ID: 21959138
[TBL] [Abstract][Full Text] [Related]
4. Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus.
Martin M; Smoląg KI; Björk A; Gullstrand B; Okrój M; Leffler J; Jönsen A; Bengtsson AA; Blom AM
Arthritis Res Ther; 2017 Dec; 19(1):266. PubMed ID: 29208014
[TBL] [Abstract][Full Text] [Related]
5. Complement C4d as a biomarker for systemic lupus erythematosus and lupus nephritis.
Qin S; Wang X; Wang J; Wu H
Lupus; 2024 Feb; 33(2):111-120. PubMed ID: 38227433
[No Abstract] [Full Text] [Related]
6. Glomerular c4d staining can be an indicator of disease activity in lupus nephritis.
Sahin OZ; Gurses S; Taslı F; Yavas H; Ersoy R; Uzum A; Cirit M
Ren Fail; 2013; 35(2):222-5. PubMed ID: 23176021
[TBL] [Abstract][Full Text] [Related]
7. Urinary C3d is elevated in patients with active Lupus nephritis and a fall in its level after 3 months predicts response at 6 months on follow up.
Ganguly S; Majumder S; Kumar S; Gupta R; Muhammed H; Shobha V; Aggarwal A; Misra R
Lupus; 2020 Nov; 29(13):1800-1806. PubMed ID: 32807020
[TBL] [Abstract][Full Text] [Related]
8. Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.
Mejia-Vilet JM; Gómez-Ruiz IA; Cruz C; Méndez-Pérez RA; Comunidad-Bonilla RA; Uribe-Uribe NO; Nuñez-Alvarez CA; Morales-Buenrostro LE
Clin Rheumatol; 2021 Jun; 40(6):2233-2242. PubMed ID: 33170371
[TBL] [Abstract][Full Text] [Related]
9. Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis.
Adhya Z; El Anbari M; Anwar S; Mortimer A; Marr N; Karim MY
Lupus; 2019 May; 28(6):713-721. PubMed ID: 31046570
[TBL] [Abstract][Full Text] [Related]
10. Activation of the alternative complement pathway predicts renal outcome in patients with lupus nephritis.
Kim H; Kim T; Kim M; Lee HY; Kim Y; Kang MS; Kim J
Lupus; 2020 Jul; 29(8):862-871. PubMed ID: 32408850
[TBL] [Abstract][Full Text] [Related]
11. Glomerular C4d deposition indicates in situ classic complement pathway activation, but is not a marker for lupus nephritis activity.
Kim SH; Jeong HJ
Yonsei Med J; 2003 Feb; 44(1):75-80. PubMed ID: 12619178
[TBL] [Abstract][Full Text] [Related]
12. Serum uric acid as a predictor for nephritis in Egyptian patients with systemic lupus erythematosus.
Hafez EA; Hassan SAE; Teama MAM; Badr FM
Lupus; 2021 Mar; 30(3):378-384. PubMed ID: 33323012
[TBL] [Abstract][Full Text] [Related]
13. The Spectrum of C4d Deposition in Renal Biopsies of Lupus Nephritis Patients.
Ding Y; Yu X; Wu L; Tan Y; Qu Z; Yu F
Front Immunol; 2021; 12():654652. PubMed ID: 34276649
[TBL] [Abstract][Full Text] [Related]
14. Renal C4d is a potential biomarker of disease activity and severity in pediatric lupus nephritis patients.
Wang X; Fu S; Yu J; Tang D; Wu H; Xu Z
Front Pediatr; 2023; 11():1193917. PubMed ID: 37325343
[TBL] [Abstract][Full Text] [Related]
15. Peritubular capillary C4d deposition in lupus nephritis different from antibody-mediated renal rejection.
Li SJ; Liu ZH; Zen CH; Wang QW; Wang Y; Li LS
Lupus; 2007; 16(11):875-80. PubMed ID: 17971360
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
[TBL] [Abstract][Full Text] [Related]
17. Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients.
Dedong H; Feiyan Z; Jie S; Xiaowei L; Shaoyang W
Immunol Lett; 2019 Jun; 210():33-39. PubMed ID: 31004679
[TBL] [Abstract][Full Text] [Related]
18. Using plasma circRNA_002453 as a novel biomarker in the diagnosis of lupus nephritis.
Ouyang Q; Huang Q; Jiang Z; Zhao J; Shi GP; Yang M
Mol Immunol; 2018 Sep; 101():531-538. PubMed ID: 30172209
[TBL] [Abstract][Full Text] [Related]
19. Blood ceramides as novel markers for renal impairment in systemic lupus erythematosus.
Patyna S; Büttner S; Eckes T; Obermüller N; Bartel C; Braner A; Trautmann S; Thomas D; Geiger H; Pfeilschifter J; Koch A
Prostaglandins Other Lipid Mediat; 2019 Oct; 144():106348. PubMed ID: 31301404
[TBL] [Abstract][Full Text] [Related]
20. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis.
Cohen D; Koopmans M; Kremer Hovinga IC; Berger SP; Roos van Groningen M; Steup-Beekman GM; de Heer E; Bruijn JA; Bajema IM
Arthritis Rheum; 2008 Aug; 58(8):2460-9. PubMed ID: 18668574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
